marcus evans, Hotel Majestic Barrière, Cannes, France
20-22 March 2004
The Conference Programme: The wide variety of conference sessions will enable delegates to explore new strategies and technologies critical to the development of the drug discovery process. The programme is put together through extensive on-going research with delegates, industry experts and relevant parties to ensure that its content is relevant and accurately reflects their needs and interests. The sessions will include: Keynote Lectures presented by leading professionals who will address topics of primary interest to delegates. They will examine current strategic trends and provide a vision for the future of the BioPharma industry. Seminars specially designed for larger groups, these sessions will involve a presentation followed by question time. A number of case study presentations by pioneering practitioners will be delivered in this format. Workshops, Think Tanks and Discussion Groups, these sessions are designed for smaller groups and will follow a highly interactive format, encouraging a high level of participation, and exchange of ideas. One-to-One Business Meetings provide an unparalleled opportunity for delegates to meet with senior representatives from solution providers, and focus on the issues most relevant to their current needs and strategies. A scheduling software is used to process the meeting requests of all attendees. Mutually requested meetings have the highest priority. Individual schedules are generated enabling thorough research and preparation to make the actual meeting time at the event more effective.
|
|
|
Invited Speakers:
|
|
Some of the confirmed speakers at Discovery 2004. Dr Howard Bilofsky, Former Director, Knowledge and Information Technologies & Alliances/R&D IT, GlaxoSmithKline and Senior Fellow, School of Engineering and Applied Science, University of Pennsylvania Dr Henry Stemplewski, Preclinical Assesor, Medicines & Healthcare products Regulatory Agency (MHRA) Richard Kitney OBE, Professor of Biomedical Systems Engineering, Imperial College of Science, Technology & Medicine Dr Mary Bendig, Manager, Drug Discovery Research, WHO Dr Tony Jones, Director, London Biotechnology Network Dr Jean Pierre Gorvel, Group Leader, Immunology and Cell Biology of Host-Bacteria Interactions, Centre d'Immunologie de Marseilles-Luminy Dr Dominik Escher, Chief Executive Officer, ESBATech AG Dr Francesc Cabré, Head of Preclinical Pharmacology, Grupo Vita
|
|